Background: People who inject drugs (PWID) are at increased risk for human immunodeficiency virus (HIV). Women who inject are a particularly vulnerable group. Preexposure prophylaxis (PrEP) is effective, but access and uptake has been limited. This study evaluated interest and concerns around oral and injectable PrEP among PWID based on gender.
Methods: This cross-sectional analysis of survey data from 8 sites in the United States (n = 284) assessed attitudes and interest in PrEP. Demographics, HIV risk behaviors, and attitudes toward PrEP were described overall and by self-identified gender (female vs male).
Results: Participants completed the PrEP survey between 2019 and 2021. The mean (standard deviation) age was 44.6 (11.4) years, 29% female, and 66% White. Mean self-perceived HIV risk score (0-10) was 2.3 (standard deviation 2.0). Interest in injectable PrEP (49.5%) was significantly higher than interest in daily oral PrEP (20.1%) (P ≤ 0.001). The most cited concerns were medication side effects (53%) and medication interactions (39.2%). Perceived HIV risk and PrEP concerns were not significantly different between genders.
Conclusions: There was high interest in injectable PrEP, particularly among females. The top concerns were medication side effects and medication interactions. These results suggest high acceptability of injectable PrEP among PWID. Future research could explore the advantages identified by female participants as well as implementation strategies for access and uptake among this vulnerable population.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/ADM.0000000000001440 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Interest in Injectable and Oral PrEP for HIV Prevention Among Women and Men Who Inject Drugs.
J Addict Med
January 2025
From the Division of General Internal Medicine, Department of Medicine, University of Washington, Seattle, WA (EPB, JIT); Department of Public Health Sciences, Clemson University, Clemson, SC (MH, SSL); School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada (LBS); Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD (SM); Division of HIV, Infectious Diseases, and Global Medicine, Department of Medicine, University of California, San Francisco, San Francisco, CA (PL); Department of Pharmacy Practice and Clinical Research, University of Rhode Island, Kingston, RI (LET); West Virginia University School of Medicine, Morgantown, WV (JF); Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA (AK); Department of Medicine, Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY (BN); Department of Psychology, Clemson University, Clemson, SC (IP-V); University of New Mexico Health Sciences Center, Department of Internal Medicine, University of New Mexico, Albuquerque, NM (KP); and Department of Medicine, University of South Carolina School of Medicine, Greenville, SC (AHL).
Background: People who inject drugs (PWID) are at increased risk for human immunodeficiency virus (HIV). Women who inject are a particularly vulnerable group. Preexposure prophylaxis (PrEP) is effective, but access and uptake has been limited.
View Article and Find Full Text PDFPrEP15-19 Choices: an implementation study protocol of HIV prevention with oral and long-acting injectable cabotegravir PrEP in real-word settings among sexual and gender minority adolescents in Brazil.
BMJ Open
January 2025
Departamento de Medicina Preventiva, Faculdade de Medicina, Universidade de São Paulo, São Paulo, São Paulo, Brazil.
Introduction: Long-acting injectable (LAI) cabotegravir is a promising new method for preventing HIV. Safe and effective long-acting agents for pre-exposure prophylaxis (PrEP) for HIV infection are needed to increase preventive options among sexual and gender minority adolescents.
Methods And Analysis: This is a multisite, prospective implementation study of three PrEP modalities (LAI-PrEP, event-driven (ED) and daily oral), using a mixed-method design with quantitative and qualitative approaches.
Preferences for HIV PrEP care among gay, bisexual, and other men who have sex with men: a large discrete choice experiment.
AIDS
January 2025
Institute for Implementation Science in Population Health (ISPH), City University of New York (CUNY), New York, New York, USA.
Objective: We aimed to identify preferences for PrEP care among diverse gay, bisexual, and other men who have sex with men (BLGBM) in the US with discrete choice experiment (DCE).
Design: We conducted two DCEs to elicit care delivery preferences for Starting and Continuing PrEP among 16-49 year-old HIV negative GBM not using PrEP from across the United States. DCEs assessed preferences for care options including location, formulation (pills, injectable), lab testing, and costs.
Association between homelessness and PrEP uptake among men who have sex with men: Results from the American Men's Internet Survey, 2017-2021.
Soc Sci Med
January 2025
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Background: Gay, bisexual, and other men who have sex with men (GBMSM) are disproportionately affected by housing insecurity across the US. This study examined the association between homelessness and uptake of pre-exposure prophylaxis (PrEP) for HIV prevention among GBMSM in the United States and investigated the modifying effect of injection drug use.
Methods: 47,750 cisgender GBMSM who participated in the American Men's Internet Survey from 2017 to 2021 and who self-reported not living with HIV were included in this secondary, cross-sectional analysis.
Preference for HIV Pre-exposure Prophylaxis Access Among Men who Have Sex With Men in China: A Discrete Choice Experiment.
Open Forum Infect Dis
January 2025
Melbourne Sexual Health Centre, Alfred Health, Melbourne, Australia.
Background: HIV pre-exposure prophylaxis (PrEP) is highly effective but not widely used by men who have sex with men (MSM; 27%) in China.
Methods: In June 2023, an online cross-sectional survey with a discrete choice experiment (DCE) was distributed to PrEP-eligible MSM in China who were at least 18 years old. The DCE explored attributes of PrEP modality (daily pill, on-demand pill, injections, implants), clinical care model (same-day, 2-visit, telehealth prescription), medication pickup (clinic, community health center, pharmacy, MSM-focused community-based organization, home delivery), enhanced support (self-management, smartphone app, text reminder, anonymous peer support group), and cost.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!